Publicaciones en las que colabora con Jesús Santos González (21)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection

    Enfermedades Infecciosas y Microbiologia Clinica

  3. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  3. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 9, pp. 653-661

2015

  1. Cardiovascular risk factors and lifetime risk estimation in hiv-infected patients under antiretroviral treatment in Spain

    HIV Clinical Trials, Vol. 16, Núm. 2, pp. 57-65

  2. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  3. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  4. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)

    Enfermedades infecciosas y microbiologia clinica

2007

  1. Cervical lipomatosis in HIV-infected patients: A case-control study

    HIV Medicine, Vol. 8, Núm. 1, pp. 17-21

  2. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

2006

  1. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment- experienced patients with adverse events related to prior NRTI use: Data from a prospective, observational, multicenter study [3]

    Journal of Acquired Immune Deficiency Syndromes